Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Colistin, ATC J01XB01 für die Zeit 01.08.2026 - 31.07.2028 (zzgl. Verlängerungsoption 1x12 Monate)
Opportunity Score
Confidence: 60%
Complexity: low
1086 days
Deadline
supplies
Contract
Deep Portfolio Analysis
- Company fit score
- Missing certificates
- Eligibility blockers
- Bid / No-Bid recommendation
AI Analysis Summary
Non-exclusive discount agreement (Rabattvereinbarung) for Colistin (ATC J01XB01) under § 130a Abs. 8 SGB V. The tender uses an open enrollment model allowing any pharmaceutical company to join at any time during the contract period (01.08.2026 – 31.07.2028, with optional 12-month extension). The agreement ends automatically when an exclusive contract is awarded. Published by DAK-Gesundheit, Germany. Submission via email only.
Strengths
Documents available
Open procedure
Low complexity
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
- Submit offer letter, signed contract with acknowledgment of specified discounts, and completed Annexes 1 and 2 (Excel)
- Annex 2 must be submitted as Excel file to [email protected]
- Submission only via email to [email protected] (no postal or portal submissions)
Buyer
Lots (1)
Single lot covering all pharmaceutical products containing Colistin (ATC J01XB01). Open enrollment model with no selection process.
Procurement Details
Publication
14 Jun 2026
Deadline
05 Jun 2029, 10:00
Procedure
open
Contract
supplies
Duration
24 MONTH
Language
DEU
Publication #
406977-2026
Classification
Performance: Germany
Documents (2)
Opportunity Score
Confidence: 60%
Complexity: low
1086 days
Deadline
supplies
Contract
Deep Portfolio Analysis
- Company fit score
- Missing certificates
- Eligibility blockers
- Bid / No-Bid recommendation